Follow The Filings

OCGN Ocugen

Ocugen earnings company data as of 9:00 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by OCGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All OCGN insider trades
  • $26K bought by 1 insider
  • None no sales outside a trading plan
  • $1.1M sold by 1 insider under 10b5-1 plans
  1. Shankar Musunuri CEO
    Planned sale
    $500K 525,991 shares at $0.9500
    Traded Oct 9 Filed Oct 13
  2. Shankar Musunuri CEO
    Planned sale
    $589K 525,991 shares at $1.12
    Traded Sep 9 Filed Sep 11
  3. Treerita Essalima Johnson-Greene CFO
    Buy
    $26K 21,000 shares at $1.23 +4.2% to stake
    Traded Jun 15 Filed Jun 17

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises and 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,9.01
8-K 1.01,7.01,8.01,9.01
8-K 5.07
8-K 5.07
8-K 7.01,8.01,9.01
DEFA14A
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A DEFA 14A
SCHEDULE 13G —
8-K 8.01,9.01
8-K 5.07,8.01
8-K 5.02
8-K 2.03,3.02,7.01,9.01
8-K 5.02,8.01
10-Q
8-K 1.01,1.02,2.02,2.03,3.02,9.01
8-K 2.02,8.01,9.01
8-K 2.02,7.01,8.01,9.01
DEF 14A
DEFA14A
SCHEDULE 13G —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.